If a proposed rule becomes final, you may get more coverage
However, usage should be overseen by a healthcare provider
You should expect questions like: What exactly are your symptoms, and how long have they been going on
For individuals taking these drugs to treat obesity, achieving weight loss targets may lead to intentional discontinuation
This activation increases insulin secretion in response to elevated blood glucose, suppresses glucagon release, and slows gastric emptying , leading to stabilized blood sugar levels and improved metabolic function
Several licensed options are currently available in the UK, including semaglutide 2.4 mg (Wegovy), tirzepatide (Mounjaro), orlistat, liraglutide 3 mg (Saxenda), and naltrexone/bupropion (Mysimba)